Results 161 to 170 of about 80,161 (286)

Using the BRAVO Risk Engine to Predict Cardiovascular Outcomes in Clinical Trials With Sodium-Glucose Transporter 2 Inhibitors. [PDF]

Diabetes Care, 2020
Shao H, Shi L, Fonseca VA.
europepmc   +1 more source

Coordination‐Tuned Iridium Single‐Atom Nanozymes Boost Multienzyme Activity for Colorimetric Sensing

Advanced Science, EarlyView.
Breaking the coordination symmetry of Ir single‐atom sites through asymmetric Ir–N3S1 engineering tailors interfacial electron transfer, oxygen activation, and multienzyme‐like catalytic pathways. Operando spectroscopy and theoretical modeling uncover the atomic‐level origin of activity enhancement, providing a strategy for designing multifunctional ...
Tao Li, Xinyu Zhang, Jiashan Xia, Mengyu Wu, Cong Liu, Yapei Sun, Wanjiang Zhao, Min Qian, Wei Wang, Weixia Duan, Shangcheng Xu   +10 more
wiley   +1 more source

Sodium-glucose transporter 2 inhibitors and cardiovascular-kidney-metabolic syndrome: a narrative review. [PDF]

Front Endocrinol (Lausanne)
Wang Y, Wang Y, He X, Li X.
europepmc   +1 more source

Hollow Cu2O Nanozymes Enhance Probiotic Therapy for Colitis via Redox Homeostasis and TXNIP/NLRP3 Inflammasome Inhibition

Advanced Science, EarlyView.
Hollow cuprous oxide (H‐Cu2O) nanozymes feature enlarged catalytic surfaces for superior reactive oxygen species (ROS) scavenging. By efficiently neutralizing mucosal ROS, H‐Cu2O directly suppresses the TXNIP/NLRP3 inflammasome axis and restores intestinal epithelial barrier integrity.
Guangzhao Wang, Jialing Cao, Pengfei Li, Yujie Wang, Shiqi Lu, Kangliang Sheng, Shan Gao, Yongzhong Wang   +7 more
wiley   +1 more source

Urinary tract infections, risk factors and antimicrobial resistance patterns in heart failure patients on sodium-glucose transporter 2 inhibitors: Evidence from Jakaya Kikwete Cardiac Institute in Tanzania. [PDF]

PLoS One
Kaaya J, Manguzu MA, Buma D, Mlyuka H, Rweyemamu S, Ntukula A, Ilomo HB, Bukundi E, Sangeda R, Mutagonda RF.   +9 more
europepmc   +1 more source

Neuropeptide Y—Graphene Oxide Complexes Inhibit Amygdala NPY‐Receptor Expressing Glutamatergic Pathways and Selectively Remove Aversive Memory In Vivo

Advanced Science, EarlyView.
A graphene oxide nanocarrier presents neuropeptide Y specifically to NPY receptor‐expressing pathways in the amygdala, whose activation selectively suppresses aversive memory formation, without modulating anxiety responses. This circuit‐restricted drug release strategy may impact future design of neuropsychiatric therapies with limited off‐target ...
Elisa Pati, Audrey Franceschi Biagioni, Raffaele Casani, Luis M. Arellano, Tommaso Battisti, Gloria Garcia‐Ortega, Neus Lozano, Alberto Bianco, Kostas Kostarelos, Laura Ballerini, Giada Cellot   +10 more
wiley   +1 more source

Reduced Incidence of Aortic Dissection in Patients With Type 2 Diabetes Treated With Sodium Glucose Transporter 2 Inhibitors. [PDF]

J Am Heart Assoc
Chung CJ, Lu HY, Chung MC, Wu LY, Huo C, Kuo LK, Liu CC, Chuu CP.   +7 more
europepmc   +1 more source

Effects of different dosages of Sodium-Glucose Transporter 2 Inhibitors on lipid levels in patients with type 2 diabetes mellitus: A protocol for systematic review and meta-analysis. [PDF]

Medicine (Baltimore), 2020
Cai T, Gao Y, Zhang L, Yang T, Chen Q.
europepmc   +1 more source

Disrupting Helicobacter pylori Iron Homeostasis With Bismuth Nanodrug‐Mediated Nutritional Trap for Targeted Gastric Infection Therapy

Advanced Science, EarlyView.
A “nutritional trap” strategy centered on disrupting bacterial iron homeostasis is proposed. The synthesized Bi‐TP@FU (TBF) can target Helicobacter pylori, interfere with the bacterial iron uptake and utilization processes to disrupt its iron homeostasis, induce bacterial death, and meanwhile preserve the balance of the intestinal flora.
Tianye Fang, Jinzhe Tong, Feng Feng, Cong Liu, Chang Shu, Jiaying Zhu, Shibo Zhang, Shuyue Deng, Wanchao Zuo, Yuhan Song, Jun Yang, Yanmin Ju, Yingying Xing, Jianjun Dai   +13 more
wiley   +1 more source

Long-term effects of metformin versus sodium glucose transporter 2 inhibitors on cardiovascular outcomes in patients with type 2 diabetes. [PDF]

Am J Transl Res
Hao X, Cui J, Zhang M, Zhang D.
europepmc   +1 more source